Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — 38th Annual J.P. Morgan Healthcare Conference (January 2020)
24 slides from Precigen's conference presentation, Jan 15, 2020
Slide 1: Precigen, Inc. at 38th Annual J.P. Morgan Healthcare Conference
Precigen, Inc. Helen Sabzevari, PhD President & CEO 14 January 2020 38th Annual J.P. Morgan Healthcare Conference Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this presentation are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking
Slide 3: Intrexon: Becoming dedicated healthcare company operating as Precigen
Intrexon: Becoming dedicated healthcare company operating as Precigen Announced January 2, 2020 Name to be Precigen with expected stock symbol of ‘PGEN’ Assets to encompass wholly-owned subsidiaries Precigen, ActoBio Therapeutics, Exemplar Genetics and majority ownership interest in Triple-Gene Incr
Slide 4: Precigen: Maximizing platform technology utilization
Precigen: Maximizing platform technology utilization Shared focus on immuno-oncology, infectious disease, cardiovascular disease, and autoimmune disorders Microbe-based agents that deliver disease-modifying therapeutics Multiple clinical and preclinical candidates Key interim data in 2020 Next gener
Slide 5: Precigen's strategic objectives and vision for patients
FISCAL STRENGTH Significant cash runway to deliver value inflection RAPID EXECUTION Focus on rapid execution of priority programs with the highest probability of success Precigen’s strategic objectives allow us to deliver on our vision for patients ACTIVE PORTFOLIO MANAGEMENT Continuous evaluation o
Slide 6: Precigen's technology platforms provide a strong foundation for precision medicine
CONTROL gene expression and regulation to drive safety CONSTRUCT powerful gene programs to drive efficacy DELIVER gene programs via viral, non-viral, and microbe- based approaches to drive lower costs Precigen’s technology platforms provide a strong foundation to realize core promise of precision me
Slide 7: Robust clinical pipeline of internal and partnered programs
PRODUCT PLATFORM INDICATION DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 STATUS / MILESTONES PARTNER PRECIGEN AG019 ActoBiotics Type 1 Diabetes Interim data in 3Q20 PRGN-3005 UltraCAR-T Ovarian Cancer Initial data in 2H20 PRGN-3006 UltraCAR-T AML, MDS Initial data in 2H20 INXN-4001 Non-viral UltraV
Slide 8: Robust preclinical pipeline to drive long-term value creation
TA PRODUCT PLATFORM INDICATION DISCOVERY PRECLINICAL PHASE 1 MILESTONES Immuno-oncology PRGN-2009 OTS AdenoVerse Immunotherapy HPV+ Cancers Phase 1 initiation 2020 PRGN-2011 AdenoVerse Cytokine Therapy Solid Tumors PRGN-5001 Multifunctional Therapeutic Solid Tumors IND-enabling studies 2020 PRGN-300
Slide 9: Disrupting the market: UltraCAR-T delivered one day after non-viral gene transfer
Disrupting the market: Precigen’s UltraCAR-T™ treatment is delivered to patients one day after non-viral gene transfer Reliance on viral vectors Complexity of manufacturing viral vectors Long and complex CAR-T cell manufacturing process Long delays for patients High cost of manufacturing Exhausted T
Slide 10: PRGN-3005 UltraCAR-T, a first-in-class therapy in ovarian cancer
PRGN-3005 UltraCAR-T™, a first-in-class therapy in ovarian cancer Target & Patient Population Preferentially targets MUC16+ cancer cells MUC16 overexpressed on >80% of ovarian tumors Limited expression found in healthy tissues Initial target is advanced stage platinum resistant ovarian cancer 300k d
Slide 11: PRGN-3006 UltraCAR-T, a first-in-class therapy in AML
PRGN-3006 UltraCAR-T™, a first-in-class therapy in AML Target & Patient Population CD33 is overexpressed on myeloid leukemia cells and leukemic stem cells 85-90% of AML patients show expression of CD33 on blasts 20k diagnosed in US in 20181 with relapsed or refractory AML Higher risk myelodysplastic
Slide 12: PRGN-2009 off-the-shelf AdenoVerse immunotherapy for HPV+ cancers
PRGN-2009 off-the-shelf AdenoVerse™ immunotherapy for HPV+ cancers Target & Patient Population Designed to activate immune system to recognize and target HPV+ solid tumors HPV+ cancers represent significant health burden in head and neck, cervical, vaginal and anal cancer Gorilla adenoviral vector w
Slide 13: Multifunctional therapeutics overcome tumor microenvironment immunosuppression
Multifunctional therapeutics overcome tumor microenvironment immunosuppression and improve T cell function compared to anti-PD1 in preclinical mouse models Multifunctional Therapeutic Platform Simultaneously targets multiple pathways to address senescence and trafficking of T lymphocytes in tumor mi
Slide 14: AG013 for oral mucositis
AG013 for oral mucositis (OM) AG013 is oral solution of ActoBiotics™ to deliver human Trefoil Factor 1 (hTFF1) to mucosal tissues Ease of administration Target & Patient Population OM is a side effect of chemo/radiation therapy in patients treated for head & neck cancer and other solid tumors No dru
Slide 15: AG013 Phase 1b data: Demonstrated efficacy vs placebo
AG013 Phase 1b data: Demonstrated efficacy vs placebo * Ulcerative Oral Mucositis (UOM) : WHO score ≥ 2 Limaye et al., 2013, Cancer Clinical Trial Design Phase 1b single blind, placebo-controlled study; 6 centers in the US Study measured safety and tolerability of locally-applied AG013 in head and n
Slide 16: AG019, a first-in-class therapy for type 1 diabetes
AG019, a first-in-class therapy for type 1 diabetes (T1D) Target & Patient Population First-in-class disease modifying antigen-specific immunotherapy to prevent, delay or reverse T1D Recent-onset T1D patients (children and adults) with residual functional Beta-cell mass Phase 1b/2a Clinical Trial On
Slide 17: INXN-4001, novel gene therapy product for heart failure
INXN-4001, novel gene therapy product for heart failure (HF) Target & Patient Population Heart failure is a complex, multi-modal and progressive disease that requires targeting multiple pathways for successful outcome Therapeutic options for end-stage HF are limited Three effector genes in INXN-4001
Slide 18: INXN-4001 Phase 1 trial: Initial data shows improvement in cardiac function
INXN-4001 Phase 1 trial: Initial data shows improvement in cardiac function and no product related adverse events First-in-human, phase I, open label, safety study of INXN-4001 delivered via RCSI1 in stable patients with implanted, outpatient LVAD3 for mechanical support of end stage HF Assessments
Slide 19: Precigen in 2019: Demonstrated achievement of milestones
Precigen in 2019: Demonstrated achievement of milestones þ þ þ þ þ ‡ ‡Wholly owned subsidiary Precigen, Inc. will be renamed in connection with parent company name change. Initiate PRGN-3006 UltraCAR-T TM Phase 1 trial in AML and MDS Rapidly advance PRGN-3005 UltraCAR-T TM for solid tumor Rapidly ad
Slide 20: Capital allocation priorities for 2020
Capital allocation priorities for 2020
Slide 21: Precigen in 2020: Multiple upcoming clinical milestones for value creation
Precigen in 2020: Multiple upcoming clinical milestones for value creation Initial data from IP arm of PRGN-3005 UltraCAR-T TM Phase 1 trial in Ovarian Cancer Initial data from PRGN-3006 UltraCAR-T TM Phase 1 trial in AML and MDS Interim data from Phase 2 trial of AG013 in Oral Mucositis Interim dat
Slide 22: Precigen in 2020: Upcoming preclinical milestones
Precigen in 2020: Upcoming preclinical milestones to drive value creation in long-term Rapidly advance PRGN-2011 AdenoVerse™ cytokine therapy towards Phase 1 study Advance next generation UltraCAR-T ™ candidate in IND-enabling studies Advance autoimmune disease candidate in IND-enabling studies Adva
Slide 23: World-class platform and focused pipeline of precision medicines
Precigen: World-class platform of innovative technologies and focused pipeline of precision medicines A focused healthcare company Advancing a robust portfolio of clinical and preclinical therapies Strong balance sheet combined with fiscal discipline Multiple value creating opportunities upcoming
Slide 24: Precigen: Advancing Medicine with Precision
G PRECIGEN ADVANCING MEDICINE WITH PRECISION™ We Ga my
Intrexon — 38th Annual J.P. Morgan Healthcare Conference (January 2020) on 6ix